Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025Elke Roeb, Thomas Longerich, Tom Luedde et al.|Zeitschrift für Gastroenterologie|2022Cited by 92
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohortFabian Jost‐Brinkmann, Raphael Mohr, Münevver Demir et al.|Alimentary Pharmacology & Therapeutics|2023Cited by 57
Skeletal Muscle Composition Predicts Outcome in Critically Ill PatientsSven H. Loosen, Christoph Roderburg, Maximilian Schulze‐Hagen et al.|Critical Care Explorations|2020Cited by 55
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)Christoph Roderburg, Sven H. Loosen, Sarah Krieg et al.|European journal of medical research|2023Cited by 39
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular CarcinomaRaphael Mohr, Christoph Roderburg, Fabian Jost‐Brinkmann et al.|Frontiers in Immunology|2021Cited by 33